Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach

ConclusionShortening the infusion duration of ramucirumab from 60 to 30  min has no impact on ramucirumab exposure. Analysis of trial data found no relationship between an increased risk of immediate IRRs and a faster infusion rate. Such a change in infusion duration is unlikely to affect the clinical efficacy or overall safety profile of ramucirumab.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research